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Summary Following chemotherapy for metastatic nonseminomatous testicular cancer, 86 patients with
normal serum markers AFP and HCG underwent resection of residual tumour masses (63 laparotomy, 11
thoracotomy, 12 both). Prognostic factors for relapse and survival were analysed with Kaplan-Meier curves
and Cox regression analysis. Putative prognostic factors included age, the primary histology, prechemotherapy
level of the tumour markers AFP and HCG, the extent of disease (lymph nodes, lung and hepatic metastases)
before and after chemotherapy, the histology of the resected material and the completeness of the surgical
procedure. Eleven patients relapsed during follow-up (median 47 months), accounting for a 5 year relapse free
percentage of 87.4%. Adverse prognostic factors were (1) prechemotherapy level of HCG (> 10,000 IU 1- ; (2)
incomplete resection; and (3) the extent of disease, especially of lung metastases (prechemotherapy number
<3,4-19, > 20; or size after chemotherapy > 1 cm; or presence of any residual lung metastasis after
chemotherapy without residual abdominal metastases). The histology found at resection was not associated
with the risk of relapse, which might be explained by the effectiveness ofpostresection chemotherapy, which in
the majority of these patients was a salvage regimen rather than two further cycles of the initial cytostatics. A
good and a poor risk group were formed, based on HCG level and completeness of resection. The effect of
salvage chemotherapy after resection of viable cancer cells needs further investigation.
Cisplatin combination chemotherapy yields a 60-80% cure
rate in metastatic nonseminomatous germ cell tumours
(NSGCT) of the testis (Peckham, 1988; Stoter et al., 1989;
Einhorn, 1990). If residual masses are detected after
chemotherapy, surgical resection is usually performed
(Donohue & Rowland, 1984), although no general agreement
exists whether all patients should be operated on (Levitt et
al., 1985; Donohue et al., 1987; Fossa et al., 1992). Addi-
tional chemotherapy is usually given if viable cancer cells are
present in the resected specimens, to kill remaining micro-
scopic disease (Donohue & Rowland, 1984). It has been
suggested that the type of additional chemotherapy should
preferably be a salvage regimen, rather than two further
cycles of the initial chemotherapy (Toner et al., 1990).
The goal of this study was to analyse the prognosis of
patients after resection of residual masses detected on CT
scan, while tumour markers were normal. Study parameters
were relapse of tumour and survival. Putative prognostic
factors included patient's age, the primary histology,
prechemotherapy level of the tumour markers AFP and
HCG, the extent of disease (lymph nodes, lung and hepatic
metastases) before and after chemotherapy, the histology of
the resected material and the completeness of the surgical
procedure. First, we investigated which factors univariately
affected prognosis. Further, we analysed multivariately
whether information obtained at resection (completeness and
histology) influenced the prognosis of the patients. Finally,
we tried to identify which factors were most important in
predicting relapse, combining all factors known after resec-
tion.
Patients and methods
Patients studied
We reviewed the charts of 210 consecutive patients with first
presentation of metastatic nonseminomatous testicular cancer
or seminoma with elevated tumour markers, referred to three
Dutch cancer centres. The patients were treated between July
1980 and June 1991, most of them in randomised trials of the
EORTC. Treatment consisted of cisplatin combination
chemotherapy (Peckham 1988; Einhorn, 1990). After com-
pletion ofinduction chemotherapy, the size of metastases was
determined on CT scan. If residual masses were detected
(> 1 cm). resection was planned, provided that tumour
markers were normal. If tumour markers remained elevated,
additional chemotherapy was usually given until normalisa-
tion of tumour markers, and subsequent resection was per-
formed of residual masses (n = 5). In 99 patients residual
masses were resected. Excluded were the following patients to
prevent prognostic inhomogeneity: patients not treated ac-
cording to standard protocol (e.g. treated with radiotherapy
before induction chemotherapy) (n = 7); patients with extra-
gonadal tumours (n = 3); patients who were operated while
tumour markers were above normal (n = 3). After this selec-
tion 86 patients were studied.
Patient data
All patient data were updated until October 1991. The histo-
logical diagnosis of the original testicular cancer was made in
the participating hospitals and was reviewed for patients in
EORTC trials. In the analysis, the British classification
(Pugh, 1976), was used. The disease was staged according to
the Royal Marsden Hospital classification (Peckham, 1988).
Further, the maximum transverse diameter of abdominal
masses, the maximum transverse diameter of pulmonary
tumour nodules, and the number of lung metastases were
determined on computed tomographic (CT) scan before and
after chemotherapy. The highest serum levels of AFP
(ng ml-I) and HCG (IU 1') prior to chemotherapy were
recorded. The type and number of chemotherapy regimens
were registered, before and after resection, as well as the
completeness of resection as noted by the surgeon, and the
type of histology in the resected material. The data were
divided in three groups of potential prognostic fac-
ors:factors known at the start of cytostatic treatment
('prechemotherapy factors'), factors known after
chemotherapy but before resection ('postchemotherapy fac-
Correspondence: H.J. Keizer, Department of Clinical Oncology,
University Hospital Leiden, PO Box 9600, 2300 RC Leiden, The
Netherlands.
Received 9 March 1993.
Br. J. Cancer (1993), 68, 195-200 0 Macmillan Press Ltd., 1993196 E.W. STEYERBERG et al.
tors') and factors known only after resection of the residual
mass ('resection factors').
Patient characteristics
Table I gives the characteristics of the patient population.
For each participating centre the number of patients in this
study and the period of accrual is presented. Median age of
the patients was 26.5 years. The primary histology of the
testicular cancer was predominantly MTI (teratocarcinoma,
48%) and MTU (embryonal carcinoma, 42%). Abdominal
metastases were present in 80 patients (93%), mediastinal
metastases in four (5%), supraclavicular metastases in eight
patients (9%), and lung metastases in 43 (50%), of whom ten
patients had a largest diameter > 3 cm and seven had > 20
lung metastases. Hepatic metastases were observed in seven
patients (8%), and a metastatic inguinal node in one patient.
AFP serum values were elevated (> 16 ng ml-') in 63
patients, and higher than 1000 ng ml' in 17 patients. HCG
serum values were elevated (>4 IU1`) in 60 patients with
ten over 10,000 IU 1-'. Standard chemotherapy changed dur-
ing the last decade from PVB to BEP or EP, alternating
PVB/BEP and more recently alternating to BOP/VIP
regimens. After chemotherapy, a laparotomy was performed
in the majority of the patients in the study group (63
laparotomy only, 12 laparotomy and thoracotomy). The pro-
cedure was a radical retroperitoneal lymph node dissection
Table I Characteristics of 86 patients resected for a residual mass
after chemotherapy
Factor Classification
Hospitala RCI: 24, 1983-1990
n, period AZVU: 18, 1980-1990
AZL: 44, 1981-1991
Age: median, range 26.5 years, 18-43
Primary histology 41 MTI (teratocarcinoma)
36 MTU (embryonal carcinoma)
5 MTT
2 TD (teratoma differentiated)
2 Seminoma (HCG 200 and
19.000 IU I-')
Tumour markers: AFP : 63, 117 ng ml
n elevated, median BHCG: 60, 38 IU 1`
Stage Ilb 6 none
Abdominal lymph node 10 A
metastases 33 B
37 C
Stage Illb 74 none
Mediastinal or supraclavicular 3 Ml
mestatases 1 M2
3 NI
5 N2
Stage IVb 43 none
Lung metastases 24 LI
5 L2
14 L3
Stage IVb 78 none
Other metastases 7 H+
1 soft tissue
Chemotherapyc 15 PVB, 1980-1982
n, type, period 14 EP, 1983-1984
33 BEP, 1983-1991
8 PVB/BEP, 1983-1987
6 VIP, 1987-1989
10 BOP/VIP, 1987-1990
Type of surgery 63 laparotomy
11 thoracotomy
12 both
Complete resection 78 yes, 8 no
Histology at resection 38 necrosis
32 mature teratoma
16 viable cancer cells
aRCI: Rotterdam Cancer Institute; AZVU: Free University Hospi-
tal Amsterdam; AZL: University Hospital Leiden. bRoyal Marsden
Classification. CB = bleomycin; E = etoposide; I = ifosfamide; 0 =
vincristine (oncovin); P = cisplatinum; V = vinblastine (in PVB regi-
men)/etoposide (VP-16 in VIP regimen).
(RPLND) at the University Hospital Leiden (39 patients)
and was limited to resection of all pathological masses in the
other centres (36 patients). The surgeons reported incomplete
resections in eight patients (9%). Two of these patients had
viable cancer cells. Overall, the histology of the resected
material was necrosis/fibrosis in 38 patients (44%), mature
teratoma in 32 (37%) and viable cancer cells in 16 (19%).
The malignant cells most often resembled the primary his-
tology.
Statistical analysis
The main endpoint in this study was the diagnosis of relapse
of tumour. Relapse was defined as a rise of AFP or HCG
serum levels above normal levels, or, in the absence of
elevated markers, histological proof of malignancy. Growing
mature teratoma without viable cancer cells was not con-
sidered as a relapse, because the patient's prognosis is not
directly jeopardised by this event. The relapse free period was
calculated from the date of resection and ended by relapse in
eleven patients. In the censored patients the relapse free
period ended by death due to surgery (2 patients), death to
unrelated causes (one patient after 60 months), or the most
recent visit to the hospital (72 patients, median follow-up
47.1 months [range:5.2-127.4]). Overall survival used the
endpoint death. Kaplan-Meier curves were used to describe
the relationship of single variables (Table II) and the end-
point (Kaplan & Meier, 1958), and groups were compared by
the log-rank test (Mantel, 1966). Cox regression (Cox, 1972)
was applied to model the simultaneous effect of several
variables. Significance for entry of variables was calculated
from a Likelihood Ratio (LR) statistic. The additional prog-
nostic influence of resection factors (histology, completeness)
was assessed by including these factors in Cox regression
models which already contained pre- and post-chemotherapy
factors. To identify the variables that have the most impor-
tant effect on relapse, a forward stepwise selection method
was used, with P<0.05 as an entry criterion. The Hazard
Ratios (HR) provided by these models may be interpreted as
relative risks. Continuous data from completely and incom-
Table II Potential prognostic factors for relapse (between brackets:
categorisation)
Prechemotherapy
Presentation
Age at orchidectomy (continuous)
Primary histology
Main diagnosis (MTI yes/no; MTU yes/no)
Presence of elements (Seminoma yes/no; trophoblastic yes/no)
Extent of disease
Lymph node metastases
Size ( 2, 2-5, >5cm; <5, 5-10, I0cm)
Lung metastases (yes/no)
Size (none, <3, >3 cm)
Number (none + <3, 4-19, >20; <20; >20)
Hepatic metastases (yes/no)
Number of sites (0, 1, > 2)
Markers AFP, HCG (continuous logarithm transformation)
AFP elevated (>16 ngml-i yes/no), discrete (0-999, > 1000)
HCG elevated (>4 IU V' yes/no), discrete (0-999, 1000-9999,
> 10000; 0-9999, > 10000)
One or both markers elevated (yes/no)
Postchemotherapy
Lymph metastases
Size (<1 cm and lung > 1 cm, > 1 cm)
Decrease (continuous; decrease yes/no)
Lung metastases
Size (> 1, >1 cm)
Decrease in size (continuous; decrease yes/no)
Decrease in number (continous; decrease yes/no)
Resection
Completeness of resection (complete/incomplete)
Histology at resection (necrosis/fibrosis, mature teratoma, viable
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pletely resected patients were compared by the Mann-
Whitney test, which is the non-parametric equivalent of the
classical t-test.
Results
Relapse and survival
Overall survival is shown in Figure 1. Two patients died
shortly after operation, accounting for a 2.3% operation
mortality. One patient suffered from bleomycin toxicity, the
other had postoperative cardiac problems, and both had
mature teratoma resected. Two years after resection 91.4% of
the patients were still alive (86.9% alive without relapse,
4.5% alive after relapse). After 5 years 87.2% were
alive:85.4% and 1.8% without and after relapse, respec-
tively.
Survival after relapse of the 11 patients who relapsed after
resection is depicted in Figure 2. Seven patients have died
(median 14.6 months after relapse). If the relapse occurred
early (within 2 months), subsequent survival appeared poor
(P = 0.042, log-rank test).
Figure 3 shows the relapse free Kaplan-Meier plot of all 86
patients. The 5 year relapse free percentage (5y-RF%) was
87.4%, with a 95% confidence interval (95%-Cl) ranging
from 78% to 93%. Most relapses (9/11) occurred within 12
months. One patient relapsed after 26 months. One late
relapse occurred after 123 months, while only two patients
were still at risk at that time (not displayed in Figure 1 and
3, but used in statistical analysis). This patient was incom-
pletely resected in 1980 (histology:viable cancer cells and
mature teratoma) and he relapsed in 1990 with extensive
masses in the abdomen, liver and lung. Salvage chemo-
therapy was successful and the patient had no evidence of
disease 10 months after the relapse.
Univariate relations with relapse
Univariate analyses revealed significant associations with
relapse after resection (P<0.05, log-rank test) for several of
the potential prognostic factors of Table II. These are shown
in Table III. Of the prechemotherapy factors, age or primary
histology were not significantly related with relapse. The
extent of lung metastases influenced the relapse rate:Size
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Figure 2 Survival after relapse (11 patients), stratified for relapse
free period less or greater than 2 months (P= 0.042, log-rank
test).
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Figure 1 Survival after resection. Kaplan-Meier plot showing
the percentage alive (upper line) and the percentage alive and
relapse free (lower line). Ten patients died: two shortly after
resection, seven after relapse and one at 60 months, due to
unrelated causes.
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Figure 3 Relapse after resection, censoring deaths without prior
relapse (two postoperative deaths, one at 60 months). The dotted
lines indicate the 95% confidence interval. The number at risk at
0, 24 and 60 months is shown between brackets. One late relapse
occurred after 123 months (not shown).
> 20:P= 0.007) or, more significantly, coded in three groups
(<3, 4-19, > 20:P = 0.003). The extent of lymph node
metastases, the presence of hepatic metastases or the number
of sites had P-values >0.10. For example, of 15 patients
with abdominal lymph nodes >IOcm, three relapsed (5y-
RF%:80%). Of the seven patients with hepatic metastases,
only one relapsed (5y-RF%:86%). Differences in relapse rate
were observed according to the prechemotherapv serum
HCG values (0-999, 1000-9999, > 10,000, P= 0.014;
0-9999, > 10,000, P = 0.001), contrary to the prechemo-
therapy level of AFP (P> 0.10). It is of note that of the ten
patients with HCG > 10,000 IU 1-, three of four who
relapsed, relapsed with brain metastases.
Postchemotherapy lung metastases were prognostically
important. Adverse characteristics were a postchemotherapy
lung metastasis size > 1 cm (P= 0.003) or the presence of
any lung metastasis without detectable residual abdominal
---T-
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Table III Significant prognostic factors for relapse (from Table II). n indicates the number of patients
in each category, with the observed 5 year relapse free percentage in the column 5 year-RF%. P-values
are calculated by the log-rank test
Categorisation n 5y-RF% P-value
Prechemotherapy
Number of lung metastases 0-3 67 94%
4-19 12 63% 0.003
>20 7 57%
Highest HCG serum level 0-9999 IU1- 76 91%
10000 IU1-' 10 58% 0.001
Postchemotherapy
Residual lung metastases lymph nodes > 1 cm, 77 91%
without abdominal metastases lymph nodes <1 cm and lung > 1 cm 9 56% 0.001
Size of lung metastases none or A 1 cm 71 92% 0 003
>1cm 15 67%
Resection
Completeness of resection complete 78 92% 0.0004 incomplete 8 50%
metastases (P = 0.001). No difference in relapse rate was
observed according to the decrease in size or decrease in
number of metastases.
The most significant factor for relapse was the com-
pleteness of resection (Table III). The 5y-RF% was only
50% in incompletely resected patients, compared to 92% in
completely resected patients (P = 0.0004). The histology of
the resected material had no significant relationship with
relapse:5y-RF% [95%-Cl] was 89% [73%-96%] (four
relapsed of 38), 85% [64%-94%] (four of 32) and 88%
[59%-97%] (3 of 16) for necrosis, mature teratoma and
cancer respectively (P = 0.89).
Prognostic influence ofresection
The extent of disease was significantly correlated with the
completeness of resection:incomplete abdominal resections
occurred more frequently in large lymph nodes (before and
after chemotherapy, P = 0.023 and P = 0.020, respectively,
Mann-Whitney test) and incomplete lung resections occurred
more frequently if more residual nodules had to be resected
(P = 0.010, Mann-Whitney test). Because of this correlation,
the additional prognostic effect of the completeness of resec-
tion was explicitly studied while taking into account the
extent of disease. Also, correction was made for the
prechemotherapy HCG level and the centre (Leiden or other)
where the patient was resected, as the technique of
abdominal lymph node resection varied between the centres.
It then appeared that incompletely resected patients had a
much poorer prognosis than completely resected patients
(Hazard Ratio >5, P<0.02). The histology at resection
provided no additional prognostic information (P>0.20,
Likelihood Ratio test).
Multivariate prediction ofrelapse
Following a forward stepwise selection procedure (Table IV),
the completeness of resection (P = 0.004) and prechemo-
therapy HCG level (P = 0.006) appeared to be the most
important predictors of relapse. The Hazard Ratios were 8.8
and 7.9 respectively. The third variable that entered the
model was the presence of residual lung metastases without
abdominal metastases (HR = 6.8, P = 0.02). At step 3,
neither the postchemotherapy size of lung metastases (< 1 cm
or > 1 cm) nor the number of prechemotherapy lung meta-
stases (s<3, 4-19, > 20) improved the model significantly
(P = 0.15 and P = 0.34 respectively, Likelihood Ratio
test).
We used the first two factors from the stepwise selection
procedure to define a simple prognostic classification. A good
and a poor prognosis group were distinguished based on the
prechemotherapy level of HCG and the completeness of
resection (Figure 4). The good prognosis group was defined
by prechemotherapy HCG values under 10,000 IU 1-1 and a
Table IV Multivariate analysis of prognostic factors for relapse,
based on the univariately significant factors from Table III. P-values
are calculated for the likelihood ratio (LR) statistic with 1 or 2
degrees of freedom (d.f.). Step 1, 2 and 3 refer to the inclusion of
variables in the stepwise forward selection procedure
LR
Step Variable (categorisation) statistic df. P-value
1 Completeness of resection 8.3 1 0.004
(complete, incomplete)
2 Prechemotherapy HCG serum level 7.6 1 0.006
(0-9999, > 10,000 IU 1-')
3 Residual lung metastases without 5.4 1 0.02
abdominal metastases (yes/no)
3 Size of lung metastases 2.1 1 0.15
(<1 cm, >1 cm)
3 Number of lung metastases 2.2 2 0.34
(<,3, 4-19, >-,20)
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Figure 4 Relapse after resection, stratified for prechemotherapy
HCG level and completeness of resection. Good risk patients had
HCG<10,000 IU 1' and a complete resection. Poor risk patients
had HCG levels > 10,000 IU 1-', incomplete resection, or both
(P<0.001, log-rank test).
complete resection, and had an estimated 5y-RF% of 95%
(95%-C1:85%-98%). The majority of patients in this study
(69/86 = 80%) had this very favourable prognosis. The poor
prognosis group was formed by patients with HCG
> 10,000 IU I` and complete resection (5y-RF%:65%),PROGNOSIS AFTER RESECTION IN TESTICULAR NSGCT 199
patients with HCG <10,000 IU 1` and incomplete resection
(5y-RF% 57%) and patients with both HCG > 10,000 IU 1-'
and incomplete resection (relapsed:1/1). This poor prognosis
group of 17 patients had a 5y-RF% of 58% (95%-
C1:31%-77%).
Discussion
This paper describes the prognosis of 86 patients with
NSGCT of the testis, who underwent resection of residual
masses after chemotherapy, while tumour markers were nor-
mal. Residual masses had a minimum size of 1 cm. These 86
patients make up 41% of the total group of 210 patients who
received chemotherapy during the study period of approxi-
mately 11 years. Viable cancer cells were found in 16 patients
(19%).
A recent review (Fossa et al., 1992) showed that the
percentage of resected specimens containing viable cancer
cells is around 20%, and this percentage was also found in
some other recent publications (Dearnaley et al., 1991;
Jansen et al., 1991; Mead et al., 1992) and in our series.
However, the fraction of resected patients varies widely
between these studies, e.g. from around 20% (Tait et al.,
1984; Mead et al., 1992) to over 85% (Mulders et al., 1990;
Aass et al., 1991). The wide variation in the fraction of
patients in whom it was deemed necessary to undergo resec-
tion may partly be explained by the heterogeneity of the
patient groups, but also reflects the lack of agreement on the
selection criteria for surgery after chemotherapy. For
instance, there is disagreement in the definition of a post-
chemotherapy normal CT scan, varying from 'absolutely nor-
mal' (Fossa et al., 1992) to smaller than 2 cm (Newlands &
Reynolds, 1989; Mead et al., 1992). Further, it has been
advocated to perform a laparotomy in any patient with
initial abdominal lymph nodes >3 cm, even of no pathologic
mass could be detected on postchemotherapy CT scan (Toner
et al., 1990). Thus, the fraction of resected patients was as
high as 51% (Toner et al., 1990) or, when resection was
performed in practically all patients with 'absolutely normal'
CT scans:86% (Aass et al., 1991). Large European studies
reported 31% (Dearnaley et al., 1991) and 20% (Mead et al.,
1992), reflecting the policy to resect CT-detectable residual
masses only if these exceed an arbitrarily chosen size. Fur-
ther, subsets of patients have been defined (Donohue et al.,
1987; Fossa et al., 1992), for whom the mortality and mor-
bidity of resection may not be balanced by the small risk of
leaving tumour unresected.
Our analysis of prognostic factors for relapse after resec-
tion showed (Table III) that significant prechemotherapy fac-
tors were the size (>3 cm) and number of lung metastases.
Although the cut off point for the prechemotherapy number
of lung metastases at > 20 is applied rather sharply in
clinical practice, it is obvious that the change in prognosis
has a more gradual course; we found that a more accurate
categorisation of the number of lung metastases is in three
groups ( 3, 4-19, > 20). Also, the initial serum value of the
tumour marker HCG () 10,000 IU 11) has major prognostic
impact. These factors were also found in other studies to
predict relapse (Peckham, 1988; Stoter et al., 1989; Stoter et
al., 1990; Bajorin et al., 1991; Mead et al., 1992), or to
predict a complete clinical response after initial
chemotherapy (Stoter et al., 1990; Bajorin et al., 1991). Post-
chemotherapy adverse prognostic factors were the size
(>1 cm) of lung metastases, or the presence of any residual
lung metastasis without detectable residual abdominal lymph
metastases. Thus, the most important factors after chemo-
therapy and before resection, were the level of HCG and the
extent of lung metastases.
The influence of the resection factors (completeness and
histology) was studied in detail. Incompletely resected
patients had a poor prognosis (5y-RF%:50%), as was found
in other studies (Tait et al., 1984; Harding et al., 1989;
Jansen et al., 1991). The size of retroperitoneal and lung
metastases was significantly correlated with the completeness
of resection. However, the adverse prognosis of incompletely
resected patients was not explained by these factors, nor the
prechemotherapy HCG level, nor the centre where the
patient was resected. Thus, the patient had a poorer prog-
nosis if the surgeon was unable to perform a complete resec-
tion, independent of other potential prognostic factors. An
explanation for this finding might be that intrinsic tumour
characteristics, such as chemosensitivity (Jansen et al., 1991)
or grade of malignancy of distinct tumour cell populations,
are different in patients who could not be resected complete-
ly. This explanation is supported by the observation that of
the five relapses in incompletely resected patients only one
was definitely in the resection area.
The histology at resection was not related to relapse in our
patients, similar to one other report (Harding et al., 1989),
but in contrast with the observations in several other studies
(Tait et al., 1984; Geller et al., 1989; Jansen et al., 1991;
Mead et al., 1992). The observation in our study may be
explained by lack of power to detect an existing difference
due to the relatively low number of relapses. A more inter-
esting explanation is that the additional treatment after
resection has been more effective than in other studies in
controlling remaining microscopic disease, since a salvage
chemotherapy regimen was used rather than two further
cycles of the initial chemotherapy in ten of the 16 patients
with viable cancer cells resected. The other six patients
received two further cycles of the initial regimen (n = 4),
radiation therapy after eight courses of chemotherapy before
resection (n = 1), or no further treatment of a mesenchymal
tumour (n = 1). This observation supports the recommenda-
tion to change the chemotherapy regimen after resection
(Toner et al., 1990).
The question rises whether incompletely resected patients
might also benefit from a salvage regimen immediately after
resection, even when no viable cancer cells are found in the
resected material. The following observation suggests that
benefit of additional chemotherapy might be obtained in
these patients: six of the eight incompletely resected patients
had no residual malignancy diagnosed (one necrosis, five
mature teratoma). Five of these did not receive any addi-
tional chemotherapy after resection, and four relapsed. The
other three patients received additional chemotherapy (one
mature teratoma and two viable cancer cells resected) and
only one relapsed, after 123 months.
According to our simple prognostic model (Figure 4), a
poor prognosis is expected in patients with prechemotherapy
HCG values over 10,000 IU I` or an incomplete resection.
The poor progrnosis ofpatients with a high prechemotherapy
level of HCG is already being recognised by a number of
treatment groups (Stoter et al., 1990; Bajorin et al., 1991;
Mead et al., 1992), and these patients are candidates to
receive more intensive induction chemotherapy. Improvement
of the prognosis of incompletely resected patients might be
obtained by the administration ofsalvage chemotherapy after
resection, although further research has to confirm this. The
use of a salvage regimen after resection rather than two
further cycles of the same chemotherapy is also subject to
further investigation as well as more detailed recommenda-
tions for the selection of patients who would benefit from
surgical resection.
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